Rivastigmine (aka, ENA 713/carbamoylatine), an FDA-approved acetyl- and butyryl-cholinesterase inhibitor (AChEI/BuChEI), is used to treat mild-moderate AD by elevating synaptic acetylcholine (ACh) levels, under the trademark “Exelon”. This evidence concerns the gene BCHE and Alzheimer disease.